Kratom, Other Drugs Now Schedule 1 in Connecticut - Legal Reader
Connecticut has classified kratom and other drugs as Schedule I controlled substances, imposing strict prohibitions on manufacturing, distribution, and possession. This change affects any pharmaceutical business operating in or shipping to Connecticut that handles these substances.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities that produce, distribute, or use kratom or the newly scheduled drugs in Connecticut. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately upon publication of the law (effective date as per the source).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Kratom and other specified drugs are now Schedule I under Connecticut law, meaning they are illegal to manufacture, distribute, or possess except for approved research.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities that produce, distribute, or use kratom or the newly scheduled drugs in Connecticut.
What you must do
Immediately cease all manufacturing, distribution, and dispensing of these substances in Connecticut. Review inventory and supply chains to ensure no products containing these substances are sold or shipped to Connecticut.
Deadline
Immediately upon publication of the law (effective date as per the source).
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)